153 related articles for article (PubMed ID: 28574510)
1. RIP4 inhibits STAT3 signaling to sustain lung adenocarcinoma differentiation.
Kopparam J; Chiffelle J; Angelino P; Piersigilli A; Zangger N; Delorenzi M; Meylan E
Cell Death Differ; 2017 Oct; 24(10):1761-1771. PubMed ID: 28574510
[TBL] [Abstract][Full Text] [Related]
2. RIP4 upregulates CCL20 expression through STAT3 signalling in cultured keratinocytes.
Bae HC; Jeong SH; Kim JH; Lee H; Ryu WI; Kim MG; Son ED; Lee TR; Son SW
Exp Dermatol; 2018 Oct; 27(10):1126-1133. PubMed ID: 30044012
[TBL] [Abstract][Full Text] [Related]
3. RIP4 is a target of multiple signal transduction pathways in keratinocytes: implications for epidermal differentiation and cutaneous wound repair.
Adams S; Munz B
Exp Cell Res; 2010 Jan; 316(1):126-37. PubMed ID: 19818768
[TBL] [Abstract][Full Text] [Related]
4. RIP4 regulates epidermal differentiation and cutaneous inflammation.
Rountree RB; Willis CR; Dinh H; Blumberg H; Bailey K; Dean C; Peschon JJ; Holland PM
J Invest Dermatol; 2010 Jan; 130(1):102-12. PubMed ID: 19626033
[TBL] [Abstract][Full Text] [Related]
5. Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.
Miller A; McLeod L; Alhayyani S; Szczepny A; Watkins DN; Chen W; Enriori P; Ferlin W; Ruwanpura S; Jenkins BJ
Oncogene; 2017 May; 36(21):3059-3066. PubMed ID: 27893707
[TBL] [Abstract][Full Text] [Related]
6. RIP4 is an ankyrin repeat-containing kinase essential for keratinocyte differentiation.
Holland P; Willis C; Kanaly S; Glaccum M; Warren A; Charrier K; Murison J; Derry J; Virca G; Bird T; Peschon J
Curr Biol; 2002 Aug; 12(16):1424-8. PubMed ID: 12194825
[TBL] [Abstract][Full Text] [Related]
7. Activation of ERK and Mutual Regulation of Stat3 and SP1 Contribute to Inhibition of PDK1 Expression by Atractylenolide-1 in Human Lung Cancer Cells.
Xiao Q; Zheng F; Wu J; Tang Q; Wang W; Hann SS
Cell Physiol Biochem; 2017; 43(6):2353-2366. PubMed ID: 29073620
[TBL] [Abstract][Full Text] [Related]
8. S100A7 promotes lung adenocarcinoma to squamous carcinoma transdifferentiation, and its expression is differentially regulated by the Hippo-YAP pathway in lung cancer cells.
Wang R; Li Y; Hu E; Kong F; Wang J; Liu J; Shao Q; Hao Y; He D; Xiao X
Oncotarget; 2017 Apr; 8(15):24804-24814. PubMed ID: 28177901
[TBL] [Abstract][Full Text] [Related]
9. Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression.
Cicchini M; Buza EL; Sagal KM; Gudiel AA; Durham AC; Feldser DM
Cell Rep; 2017 Feb; 18(8):1958-1969. PubMed ID: 28228261
[TBL] [Abstract][Full Text] [Related]
10. ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma.
Li J; Ao J; Li K; Zhang J; Li Y; Zhang L; Wei Y; Gong D; Gao J; Tan W; Huang L; Liu L; Lin P; Wei Y
Cell Death Dis; 2016 Oct; 7(10):e2428. PubMed ID: 27763636
[TBL] [Abstract][Full Text] [Related]
11. Regulation of NF-kappaB activity and keratinocyte differentiation by the RIP4 protein: implications for cutaneous wound repair.
Adams S; Pankow S; Werner S; Munz B
J Invest Dermatol; 2007 Mar; 127(3):538-44. PubMed ID: 17039240
[TBL] [Abstract][Full Text] [Related]
12. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.
Yeddula N; Xia Y; Ke E; Beumer J; Verma IM
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681
[TBL] [Abstract][Full Text] [Related]
13. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.
Cho HC; Lai CY; Shao LE; Yu J
Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965
[TBL] [Abstract][Full Text] [Related]
14. PARVA promotes metastasis by modulating ILK signalling pathway in lung adenocarcinoma.
Huang AH; Pan SH; Chang WH; Hong QS; Chen JJ; Yu SL
PLoS One; 2015; 10(3):e0118530. PubMed ID: 25738875
[TBL] [Abstract][Full Text] [Related]
15. STAT3 activation and aberrant ligand-dependent sonic hedgehog signaling in human pulmonary adenocarcinoma.
Yang Q; Shen SS; Zhou S; Ni J; Chen D; Wang G; Li Y
Exp Mol Pathol; 2012 Oct; 93(2):227-36. PubMed ID: 22554932
[TBL] [Abstract][Full Text] [Related]
16. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas.
Tsai LH; Chen PM; Cheng YW; Chen CY; Sheu GT; Wu TC; Lee H
Oncogene; 2014 Jul; 33(29):3851-60. PubMed ID: 23995788
[TBL] [Abstract][Full Text] [Related]
17. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
19. Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model.
Floyd HS; Farnsworth CL; Kock ND; Mizesko MC; Little JL; Dance ST; Everitt J; Tichelaar J; Whitsett JA; Miller MS
Carcinogenesis; 2005 Dec; 26(12):2196-206. PubMed ID: 16051643
[TBL] [Abstract][Full Text] [Related]
20. Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas.
Li J; Sordella R; Powers S
Sci Rep; 2016 Jun; 6():27891. PubMed ID: 27301828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
